Colgate-Palmolive’s Q3 2026 earnings, due October 30 before the open, sit at the center of the near-even odds, with consensus EPS estimates clustered near $0.93–$0.95. Traders weigh the company’s four-quarter streak of beats—most recently a $0.04 Q2 outperformance—against persistent headwinds including elevated raw-material and tariff costs, softness in the U.S. market, and the drag from exiting private-label pet food. Management’s maintained 1–4% organic-sales guidance and roughly flat gross-margin outlook embed modest expectations, while recent analyst price-target reductions reflect caution on category growth. A decisive print above or below consensus, coupled with any update on advertising spend or emerging-market momentum, would likely shift the market-implied probability sharply.